Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number ...
A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither ...
Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their ...
Atherosclerosis, the process underlying most cardiovascular diseases, begins long before the first symptoms appear.
The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in ...
Silent atherosclerosis was detectable from early adulthood and showed sex-specific patterns of growth with age, according to ...
Antiplatelet monotherapy reduced bleeding but dual therapy provided greater cardiovascular event protection in patients at ...
Potent antiplatelet therapy increased bleeding without signs of benefit regarding cardiovascular events in patients with ...
Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time ...
Atorvastatin reduced major cardiovascular events by 30% in older people without known cardiovascular disease, diabetes or ...
Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial ...
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib for patients whose pancreatic cancer has spread to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results